Ann: NYX-PCSK9i In Vivo Study Exploratory Analysis Results, page-19

I hope it's a large phase I study in which they can look for early efficacy signals, rather than just safety.

Unlike trials for cancer therapeutics, regenerative medicines etc which can take years to measure efficacy; trialing a cholesterol lowering compound should be relatively fast due to massive number of possible patients, simple to measure endpoints, and short trial duration.

Surely NYX-PCSK9i would attract better licensing terms with human efficacy data behind it. I'd want to see 12-15% royalties on 5-10B USD per year.

On another note, my hunch is that Pfizer want to re-secure dominance in the cholesterol lowering market - they have to be the most likely suitor.